KẾT QUẢ ĐIỀU TRỊ UNG THƯ TUYẾN TIỀN LIỆT GIAI ĐOẠN DI CĂN KHÁNG CẮT TINH HOÀN BẰNG ABIRATERONE ACETATE VÀ MỘT SỐ YẾU TỐ TIÊN LƯỢNG

Abstract

Objective: Evaluation of outcomes with Abiraterone acetate in patients with metastatic castration-resistant prostate cancer and analysis of some factors affecting the time of treatment failure. Patients and methods: A cross-sectional descriptive study on 65 patients with metastatic castration-resistant prostate cancer in Vietnam National Cancer Hospital from January 2014 through May 2023. Results: Median age was 70,0 years (IQR: 64-76), median PSA was 34,7 ng/ml (IQR: 13,0-106,8), median hemoglobin was 126 g/l (IQR: 116,5-132,0), The rate of bone metastasis was 87,7%, lymph node metastasis was 38,5%, and the rate of visceral metastasis was 16,9%. The rate of PSA response was 73.8%, median PSA PFS was 10,5 months (95% CI: 7.4-13.6), median TTF was 15,0 months (95% CI: 11.1-18.9). In the multivariate analysis, only higher Gleason score (≥ 8), higher time from ADT start to AAP (≥ 12), PSA (> 80ng/ml), visceral metastases, and PSA response (<50% PSA decline) were associated with shorter time to TTF. Conclusion: Abiraterone acetate was well tolerated and effective in mCRPC patients with median biochemical PFS and median TTF of 10.5 months and 15.0 months.